Surface modification with c(RGDyC)-PEG improved tumor targeting and systemic clearance, and when co-loaded with doxorubicin, the system synergized with PD-L1 blockade to significantly reduce both primary and metastatic tumor burdens [231]. The gene discussed is CD274; the disease is neoplasm.